1887

Abstract

Adenovirus is a significant pathogen in immunocompromised patients and is widely utilized as a gene delivery vector, so a detailed understanding of the human immune response to adenovirus infection is critical. This study characterized the adenovirus-specific CD4 T-cell response of healthy donors by incubation with whole virus or with individual hexon and fiber proteins. Adenovirus-specific CD4 T cells averaged 0.26 % of the CD4 T-cell pool and were detectable in all donors. T cells recognizing the highly conserved hexon protein accounted for 0.09 %, whereas no response was observed against the fiber protein. A panel of hexon-specific CD4 T-cell clones was generated and shown to lyse targets infected with adenovirus from different serotypes and species. Three CD4 T-cell epitopes are described, which map to highly conserved regions of the hexon protein.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82867-0
2007-09-01
2021-03-04
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/9/2417.html?itemId=/content/journal/jgv/10.1099/vir.0.82867-0&mimeType=html&fmt=ahah

References

  1. Adhikary D., Behrends U., Moosmann A., Witter K., Bornkamm G. W., Mautner J. 2006; Control of Epstein–Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med 203:995–1006 [CrossRef]
    [Google Scholar]
  2. Bennett S. R., Carbone F. R., Karamalis F., Flavell R. A., Miller J. F., Heath W. R. 1998; Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478–480 [CrossRef]
    [Google Scholar]
  3. Bollard C. M., Kuehnle I., Leen A., Rooney C. M., Heslop H. E. 2004; Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant 10:143–155 [CrossRef]
    [Google Scholar]
  4. Bordigoni P., Carret A. S., Venard V., Witz F., Le Faou A. 2001; Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 32:1290–1297 [CrossRef]
    [Google Scholar]
  5. Brown D. M., Roman E., Swain S. L. 2004; CD4 T cell responses to influenza infection. Semin Immunol 16:171–177 [CrossRef]
    [Google Scholar]
  6. Burns D. M., Crawford D. H. 2004; Epstein–Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease. Blood Rev 18:193–209 [CrossRef]
    [Google Scholar]
  7. Chakrabarti S., Mautner V., Osman H., Collingham K. E., Fegan C. D., Klapper P. E., Moss P. A., Milligan D. W. 2002; Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 100:1619–1627 [CrossRef]
    [Google Scholar]
  8. Ebner K., Pinsker W., Lion T. 2005; Comparative sequence analysis of the hexon gene in the entire spectrum of human adenovirus serotypes: phylogenetic, taxonomic, and clinical implications. J Virol 79:12635–12642 [CrossRef]
    [Google Scholar]
  9. Einsele H., Hebart H. 2004; CMV-specific immunotherapy. Hum Immunol 65:558–564 [CrossRef]
    [Google Scholar]
  10. Engler J. A., Mulach B., Hong J. S. 1999; Characterization of the adenovirus fiber protein. In Adenovirus Methods and Protocols pp 241–259 Edited by Wold W. S. M. Totowa, NJ: Humana Press;
    [Google Scholar]
  11. Feuchtinger T., Richard C., Pfeiffer M., Neuhauser F., Lucke J., Handgretinger R., Greil J., Bader P., Klingebiel T. other authors 2005; Adenoviral infections after transplantation of positive selected stem cells from haploidentical donors in children: an update. Klin Padiatr 217:339–344 [CrossRef]
    [Google Scholar]
  12. Feuchtinger T., Matthes-Martin S., Richard C., Lion T., Fuhrer M., Hamprecht K., Handgretinger R., Peters C., Schuster F. R. other authors 2006; Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 134:64–76 [CrossRef]
    [Google Scholar]
  13. Flomenberg P., Babbitt J., Drobyski W. R., Ash R. C., Carrigan D. R., Sedmak G. V., McAuliffe T., Camitta B., Horowitz M. M. other authors 1994; Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 169:775–781 [CrossRef]
    [Google Scholar]
  14. Flomenberg P., Piaskowski V., Truitt R. L., Casper J. T. 1996; Human adenovirus-specific CD8+ T-cell responses are not inhibited by E3-19K in the presence of gamma interferon. J Virol 70:6314–6322
    [Google Scholar]
  15. Fox J. P., Brandt C. D., Wassermann F. E., Hall C. E., Spigland I., Kogon A., Elveback L. R. 1969; The virus watch program: a continuing surveillance of viral infections in metropolitan New York families VI. Observations of adenovirus infections: virus excretion patterns, antibody response, efficiency of surveillance, patterns of infections, and relation to illness. Am J Epidemiol 89:25–50
    [Google Scholar]
  16. Fox J. P., Hall C. E., Cooney M. K. 1977; The Seattle Virus Watch. VII. Observations of adenovirus infections. Am J Epidemiol 105:362–386
    [Google Scholar]
  17. Gamadia L. E., Remmerswaal E. B., Weel J. F., Bemelman F., Van Lier R. A., Ten Berge I. J. 2003; Primary immune responses to human CMV: a critical role for IFN- γ -producing CD4+ T cells in protection against CMV disease. Blood 101:2686–2692 [CrossRef]
    [Google Scholar]
  18. Garnett C. T., Erdman D., Xu W., Gooding L. R. 2002; Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol 76:10608–10616 [CrossRef]
    [Google Scholar]
  19. Haase A. T., Mautner V., Pereira H. G. 1972; The immunogenicity of adenovirus type 5 structural proteins. J Immunol 108:483–485
    [Google Scholar]
  20. Hale G. A., Heslop H. E., Krance R. A., Brenner M. A., Jayawardene D., Srivastava D. K., Patrick C. C. 1999; Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant 23:277–282 [CrossRef]
    [Google Scholar]
  21. Haveman L. M., Bierings M., Legger E., Klein M. R., de Jager W., Otten H. G., Albani S., Kuis W., Sette A., Prakken B. J. 2006; Novel pan-DR-binding T cell epitopes of adenovirus induce pro-inflammatory cytokines and chemokines in healthy donors. Int Immunol 18:1521–1529 [CrossRef]
    [Google Scholar]
  22. Heemskerk B., Veltrop-Duits L. A., van Vreeswijk T., ten Dam M. M., Heidt S., Toes R. E., van Tol M. J., Schilham M. W. 2003; Extensive cross-reactivity of CD4+ adenovirus-specific T cells: implications for immunotherapy and gene therapy. J Virol 77:6562–6566 [CrossRef]
    [Google Scholar]
  23. Heemskerk B., van Vreeswijk T., Veltrop-Duits L. A., Sombroek C. C., Franken K., Verhoosel R. M., Hiemstra P. S., van Leeuwen D., Ressing M. E. other authors 2006; Adenovirus-specific CD4+ T cell clones recognizing endogenous antigen inhibit viral replication in vitro through cognate interaction. J Immunol 177:8851–8859 [CrossRef]
    [Google Scholar]
  24. Homann D., Teyton L., Oldstone M. B. 2001; Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory. Nat Med 7:913–919 [CrossRef]
    [Google Scholar]
  25. Horwitz M. S. 2001; Adenoviruses. In Fields Virology pp 2301–2326 Edited by Fields B. N., Knipe D. M. Philadelphia: Lippincott Williams & Wilkins;
    [Google Scholar]
  26. Hromas R., Cornetta K., Srour E., Blanke C., Broun E. R. 1994; Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood 84:1689–1690
    [Google Scholar]
  27. Janssen E. M., Lemmens E. E., Wolfe T., Christen U., von Herrath M. G., Schoenberger S. P. 2003; CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421:852–856 [CrossRef]
    [Google Scholar]
  28. Kahn P. 2003; Update on Merck's AIDS Vaccine Program. IAVI Rep 7:
    [Google Scholar]
  29. Khanna R., Burrows S. R., Steigerwald-Mullen P. M., Thomson S. A., Kurilla M. G., Moss D. J. 1995; Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein–Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance. Virology 214:633–637 [CrossRef]
    [Google Scholar]
  30. Klenerman P., Hill A. 2005; T cells and viral persistence: lessons from diverse infections. Nat Immunol 6:873–879 [CrossRef]
    [Google Scholar]
  31. Kojaoghlanian T., Flomenberg P., Horwitz M. S. 2003; The impact of adenovirus infection on the immunocompromised host. Rev Med Virol 13:155–171 [CrossRef]
    [Google Scholar]
  32. Leen A. M., Rooney C. M. 2005; Adenovirus as an emerging pathogen in immunocompromised patients. Br J Haematol 128:135–144 [CrossRef]
    [Google Scholar]
  33. Leen A., Meij P., Redchenko I., Middeldorp J., Bloemena E., Rickinson A., Blake N. 2001; Differential immunogenicity of Epstein–Barr virus latent-cycle proteins for human CD4+ T-helper 1 responses. J Virol 75:8649–8659 [CrossRef]
    [Google Scholar]
  34. Leen A. M., Sili U., Vanin E. F., Jewell A. M., Xie W., Vignali D., Piedra P. A., Brenner M. K., Rooney C. M. 2004; Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood 104:2432–2440 [CrossRef]
    [Google Scholar]
  35. Leen A. M., Myers G. D., Sili U., Huls M. H., Weiss H., Leung K. S., Carrum G., Krance R. A., Chang C. C. other authors 2006; Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12:1160–1166 [CrossRef]
    [Google Scholar]
  36. Lion T., Baumgartinger R., Watzinger F., Matthes-Martin S., Suda M., Preuner S., Futterknecht B., Lawitschka A., Peters C. other authors 2003; Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 102:1114–1120 [CrossRef]
    [Google Scholar]
  37. Long H. M., Haigh T. A., Gudgeon N. H., Leen A. M., Tsang C. W., Brooks J., Landais E., Houssaint E., Lee S. P. other authors 2005; CD4+ T-cell responses to Epstein–Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol 79:4896–4907 [CrossRef]
    [Google Scholar]
  38. Lucas M., Day C. L., Wyer J. R., Cunliffe S. L., Loughry A., McMichael A. J., Klenerman P. 2004; Ex vivo phenotype and frequency of influenza virus-specific CD4 memory T cells. J Virol 78:7284–7287 [CrossRef]
    [Google Scholar]
  39. Miller G., Lipman M. 1973; Release of infectious Epstein–Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci U S A 70:190–194 [CrossRef]
    [Google Scholar]
  40. Miyamoto T., Gondo H., Miyoshi Y., Shigematsu H., Minematsu T., Takenaka K., Tanimoto K., Horiuchi T., Asano Y. other authors 1998; Early viral complications following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Br J Haematol 100:348–350 [CrossRef]
    [Google Scholar]
  41. Mullbacher A., Bellett A. J., Hla R. T. 1989; The murine cellular immune response to adenovirus type 5. Immunol Cell Biol 67:31–39 [CrossRef]
    [Google Scholar]
  42. Murakami P., McCaman M. T. 1999; Quantitation of adenovirus DNA and virus particles with the PicoGreen fluorescent dye. Anal Biochem 274:283–288 [CrossRef]
    [Google Scholar]
  43. Neumann R., Genersch E., Eggers H. J. 1987; Detection of adenovirus nucleic acid sequences in human tonsils in the absence of infectious virus. Virus Res 7:93–97 [CrossRef]
    [Google Scholar]
  44. Olive M., Eisenlohr L. C., Flomenberg P. 2001; Quantitative analysis of adenovirus-specific CD4+ T-cell responses from healthy adults. Viral Immunol 14:403–413 [CrossRef]
    [Google Scholar]
  45. Olive M., Eisenlohr L., Flomenberg N., Hsu S., Flomenberg P. 2002; The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope. Hum Gene Ther 13:1167–1178 [CrossRef]
    [Google Scholar]
  46. Rammensee H., Bachmann J., Emmerich N. P., Bachor O. A., Stevanovic S. 1999; SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213–219 [CrossRef]
    [Google Scholar]
  47. Rawle F. C., Knowles B. B., Ricciardi R. P., Brahmacheri V., Duerksen-Hughes P., Wold W. S., Gooding L. R. 1991; Specificity of the mouse cytotoxic T lymphocyte response to adenovirus 5. E1A is immunodominant in H-2b, but not in H-2d or H-2k mice. J Immunol 146:3977–3984
    [Google Scholar]
  48. Ridge J. P., Di Rosa F., Matzinger P. 1998; A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474–478 [CrossRef]
    [Google Scholar]
  49. Rowe W. P., Huebner R. J., Gilmore L. K., Parrott R. H., Ward T. G. 1953; Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 84:570–573 [CrossRef]
    [Google Scholar]
  50. Rux J. J., Kuser P. R., Burnett R. M. 2003; Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution X-ray crystallographic, molecular modeling, and sequence-based methods. J Virol 77:9553–9566 [CrossRef]
    [Google Scholar]
  51. Schoenberger S. P., Toes R. E., van der Voort E. I., Offringa R., Melief C. J. 1998; T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions. Nature 393:480–483 [CrossRef]
    [Google Scholar]
  52. Scriba T. J., Purbhoo M., Day C. L., Robinson N., Fidler S., Fox J., Weber J. N., Klenerman P., Sewell A. K., Phillips R. E. 2005; Ultrasensitive detection and phenotyping of CD4+ T cells with optimized HLA class II tetramer staining. J Immunol 175:6334–6343 [CrossRef]
    [Google Scholar]
  53. Sester M., Sester U., Alarcon S. S., Heine G., Lipfert S., Girndt M., Gartner B., Kohler H. 2002; Age-related decrease in adenovirus-specific T cell responses. J Infect Dis 185:1379–1387 [CrossRef]
    [Google Scholar]
  54. Smith C. A., Woodruff L. S., Kitchingman G. R., Rooney C. M. 1996; Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro. J Virol 70:6733–6740
    [Google Scholar]
  55. Stone D., Ni S., Li Z. Y., Gaggar A., DiPaolo N., Feng Q., Sandig V., Lieber A. 2005; Development and assessment of human adenovirus type 11 as a gene transfer vector. J Virol 79:5090–5104 [CrossRef]
    [Google Scholar]
  56. Tang J., Olive M., Pulmanausahakul R., Schnell M., Flomenberg N., Eisenlohr L., Flomenberg P. 2006; Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. Virology 350:312–322 [CrossRef]
    [Google Scholar]
  57. Thirion C., Lochmuller H., Ruzsics Z., Boelhauve M., Konig C., Thedieck C., Kutik S., Geiger C., Kochanek S. other authors 2006; Adenovirus vectors based on human adenovirus type 19a have high potential for human muscle-directed gene therapy. Hum Gene Ther 17:193–205 [CrossRef]
    [Google Scholar]
  58. Vanniasinkam T., Ertl H. C. 2005; Adenoviral gene delivery for HIV-1 vaccination. Curr Gene Ther 5:203–212 [CrossRef]
    [Google Scholar]
  59. Veltrop-Duits L. A., Heemskerk B., Sombroek C. C., van Vreeswijk T., Gubbels S., Toes R. E., Melief C. J., Franken K. L., Havenga M. other authors 2006; Human CD4+ T cells stimulated by conserved adenovirus 5 hexon peptides recognize cells infected with different species of human adenovirus. Eur J Immunol 36:2410–2423 [CrossRef]
    [Google Scholar]
  60. Vogels R., Zuijdgeest D., van Rijnsoever R., Hartkoorn E., Damen I., de Bethune M. P., Kostense S., Penders G., Helmus N. other authors 2003; Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77:8263–8271 [CrossRef]
    [Google Scholar]
  61. Xing Z., Santosuosso M., McCormick S., Yang T. C., Millar J., Hitt M., Wan Y., Bramson J., Vordermeier H. M. 2005; Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines. Curr Gene Ther 5:485–492 [CrossRef]
    [Google Scholar]
  62. Young L. S., Searle P. F., Onion D., Mautner V. 2006; Viral gene therapy strategies: from basic science to clinical application. J Pathol 208:299–318 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.82867-0
Loading
/content/journal/jgv/10.1099/vir.0.82867-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error